Efficacy and safety of regulating intestinal flora with yiqi-yangxue and tongluo prescriptions in improving left ventricular remodeling and cardiac function in patients with acute coronary syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial

Not Applicable

• Conditions: acute coronary syndrome

• Registration Number: ITMCTR2100005037
• Lead Sponsor: Qilu Hospital of Shandong University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Outpatient or inpatient patients aged 18-74 (including 18 and 74) years;
2. Meet the Western Medicine diagnostic criteria of ''Guidelines for Rapid Diagnosis and Treatment of Acute Coronary Syndrome (2019)'', the primary disease is acute coronary syndrome, and the condition is relatively stable;
3. Serum NT-proBNP level increased, aged 18-50 years, NT-proBNP>450ng/L; aged 51-74 years, NT-proBNP>900ng/L;
4. Patients who have no allergic reaction to the drugs used in this treatment;
5. Patients who are willing to sign the informed consent form and cooperate with the treatment.

Exclusion Criteria

1. Patients with severe mental disorders;
2. Patients with other heart diseases;
3. Patients who are pregnant or breastfeeding;
4. Patients with liver and kidney damage;
5. Patients with cerebral hemorrhage, gastrointestinal bleeding and other diseases;
6. Patients who are unwilling to cooperate with treatment.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-terminal pro-B type natriuretic peptide;

Secondary Outcome Measures

Name	Time	Method
Tissue Doppler measurements E';The duration of the angina attack;Tissue Doppler measurement E/e';Number of angina attacks;Frequency of angina attacks;